Endocrine Therapy Initiation From 2001 to 2008 Varies by Age at Breast Cancer Diagnosis and Tumor Size-Reference-Cited by-同舟云学术

Endocrine Therapy Initiation From 2001 to 2008 Varies by Age at Breast Cancer Diagnosis and Tumor Size

Published:2012-03 Issue:2 Volume:8 Page:113-120
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Bowles Erin J. Aiello¹,Buist Diana S.M.,Chubak Jessica,Yu Onchee,Johnson Jeanene,Chestnut Janet,Boudreau Denise M.

Affiliation:

1. Group Health Research Institute; and Group Health Physicians, Group Health Cooperative, Seattle, WA

Abstract

Differential initiation over time, as well as by age and tumor size, suggests patient preferences and provider recommendations for endocrine therapy vary, despite guideline recommendations.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology(nursing),Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JOP.2011.000417

Reference32 articles.

1. Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations

2. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review

3. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer

4. Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: Past, present and future recommendations

5. American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018;Breast Cancer Research and Treatment;2024-08-16

2. Endocrine therapy initiation among women with stage I–III invasive, hormone receptor-positive breast cancer from 2001–2016;Breast Cancer Research and Treatment;2022-03-11

3. The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study;International Journal of Clinical Oncology;2022-01-18

4. Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics;Frontiers in Oncology;2021-11-19

5. Patient and provider factors associated with the noninitiation of tamoxifen for young women at high‐risk for the development of breast cancer;The Breast Journal;2020-03